GlassScriptPhysician profile
Jason G Shultz
NPI 1245468685
$1,428.00
in general payments reported to CMS, 2019-2025
12 companies · $756 in 2025
The $756 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2021: $122 · 2022: $62.06 · 2023: $230 · 2024: $42.77 · 2025: $756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $961 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $960.56 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $486.42 | 2019-2025 | Opdivo, Krazati |
| Astrazeneca Pharmaceuticals LP | $333.69 | 2019-2025 | Imfinzi |
| Novocure INC. | $212.54 | 2022-2025 | Optune Lua (Novottf-200t), Optune |
| Genzyme Corporation | $138.89 | 2025 | |
| G1 Therapeutics, INC. | $89.33 | 2023 | Cosela |
| Janssen Biotech, INC. | $56.50 | 2021-2025 | Rybrevant |
| Abbvie INC. | $31.34 | 2025 | |
| Daiichi Sankyo INC. | $20.69 | 2025 | Datroway |
| Genentech USA, INC. | $16.51 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $15.44 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $14.92 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Shultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.